EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy

Zhuolong Zhou, Kevin Van der Jeught, Yujing Li, Samantha Sharma, Tao Yu, Ishara Moulana, Sheng Liu, Jun Wan, Paul R Territo, Mateusz Opyrchal, Xinna Zhang, Guohui Wan iD und 1 weitere

Advanced Science · 2023-08 · 10 (23)

DOI: 10.1002/advs.202300548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 04.06.2023. Verfasst von Zhuolong Zhou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vera Bradley Foundation for Breast Cancer, Indiana University Strategic Research Initiative Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDA) is a clinically challenging disease with limited treatment options. Despite a small percentage of cases with defective mismatch DNA repair (dMMR), PDA is included in the most immune‐resistant cancer types that are poorly responsive to immune checkpoint blockade (ICB) therapy. To facilitate drug discovery combating this immunosuppressive tumor type, a high‐throughput drug screen platform is established with the newly developed T cell‐incorporated pancreatic tumor organoid model. Tumor‐specific T cells are included in the pancreatic tumor organoids by two‐step cell packaging, fully recapitulating immune infiltration in the immunosuppressive tumor microenvironment (TME). The organoids are generated with key components in the original tumor, including epithelial, vascular endothelial, fibroblast and macrophage cells, and then packaged with T cells into their outside layer mimicking a physical barrier and enabling T cell infiltration and cytotoxicity studies. In the PDA organoid‐based screen, epigenetic inhibitors ITF2357 and I‐BET151 are identified, which in combination with anti‐PD‐1 based therapy show considerably greater anti‐tumor effect. The combinatorial treatment turns the TME from immunosuppressive to immunoactive, up‐regulates the MHC‐I antigen processing and presentation, and enhances the effector T cell activity. The standardized PDA organoid model has shown great promise to accelerate drug discovery for the immunosuppressive cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansT-LymphocytesImmunotherapyOrganoidsTumor Microenvironment

Stichwörter der Autor:innen

epigenetic inhibitorshigh-throughput drug screenimmunotherapypancreatic ductal adenocarcinomapatient-derived organoidtumor antigen presentationtumor organoid

Autor:innen und Institutionen

  • Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
  • Department of Medical and Molecular Genetics, Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
  • Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
  • Division of Hematology/Oncology, Department of Medicine, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
  • Department of Medical and Molecular Genetics, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
  • School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.

ORCID-Profile: Guohui Wan, Xiongbin Lu

Förderung

  • Vera Bradley Foundation for Breast Cancer
  • Indiana University Strategic Research Initiative Fund

Zitieren

APA

Zhou, Z., Van der Jeught, K., Li, Y., Sharma, S., Yu, T., Moulana, I., Liu, S., Wan, J., Territo, P. R., Opyrchal, M., Zhang, X., Wan, G., & Lu, X. (2023). A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy. Advanced Science, 10(23). https://doi.org/10.1002/advs.202300548

Vancouver

Zhou Z, Van der Jeught K, Li Y, Sharma S, Yu T, Moulana I, et al. A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy. Advanced Science. 2023;10(23). doi:10.1002/advs.202300548

BibTeX
@article{Zhou2023,
  author = {Zhou, Zhuolong and Van der Jeught, Kevin and Li, Yujing and Sharma, Samantha and Yu, Tao and Moulana, Ishara and Liu, Sheng and Wan, Jun and Territo, Paul R and Opyrchal, Mateusz and Zhang, Xinna and Wan, Guohui and Lu, Xiongbin},
  title = {A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy},
  journal = {Advanced Science},
  year = {2023},
  volume = {10},
  number = {23},
  doi = {10.1002/advs.202300548}
}
Kostenlos starten →